Literature DB >> 24619376

Kidney cancer: decreased incidence of skeletal-related events in mRCC.

Takeshi Yuasa1, Shinji Urakami1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24619376     DOI： 10.1038/nrurol.2014.56

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  The health care burden of skeletal related events in patients with renal cell carcinoma and bone metastasis.

Authors:  Carina Antczak; Vincent Q Trinh; Akshay Sood; Praful Ravi; Florian Roghmann; Vincent Trudeau; Steven L Chang; Pierre I Karakiewicz; Adam S Kibel; Nandita Krishna; Paul L Nguyen; Fred Saad; Jesse D Sammon; Shyam Sukumar; Kevin C Zorn; Maxine Sun; Quoc-Dien Trinh
Journal:  J Urol       Date:  2013-12-30       Impact factor: 7.450

Review 2.  Skeletal metastasis in renal cell carcinoma: current and future management options.

Authors:  Steven L Wood; Janet E Brown
Journal:  Cancer Treat Rev       Date:  2011-07-29       Impact factor: 12.111

3.  Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.

Authors:  Shinya Maita; Takeshi Yuasa; Norihiko Tsuchiya; Yoko Mitobe; Shintaro Narita; Yohei Horikawa; Kiyohiko Hatake; Iwao Fukui; Shinya Kimura; Taira Maekawa; Tomonori Habuchi
Journal:  Int J Cancer       Date:  2011-06-10       Impact factor: 7.396

4.  Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.

Authors:  M F Botteman; M Meijboom; I Foley; J M Stephens; Y M Chen; S Kaura
Journal:  Eur J Health Econ       Date:  2010-08-31

5.  Economic burden of renal cell carcinoma in the US: Part II--an updated analysis.

Authors:  Ya-Chen T Shih; Chun-Ru Chien; Ying Xu; I-Wen Pan; Grace L Smith; Thomas A Buchholz
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

Review 6.  Economic burden of renal cell carcinoma: Part I--an updated review.

Authors:  Ya-Chen T Shih; Chun-Ru Chien; Ying Xu; I-Wen Pan; Grace L Smith; Thomas A Buchholz
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

Review 7.  Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.

Authors:  Allan Lipton; Alejandro Colombo-Berra; Ronald M Bukowski; Lee Rosen; Ming Zheng; Gladys Urbanowitz
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

8.  Economic burden of adverse events in patients with metastatic renal cell carcinoma.

Authors:  May Hagiwara; Rohit Borker; Gerry Oster
Journal:  Clin Ther       Date:  2013-11-28       Impact factor: 3.393

9.  Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.

Authors:  Jakub Zołnierek; Pawel Nurzyński; Przemysław Langiewicz; Sylwia Oborska; Anna Waśko-Grabowska; Ewa Kuszatal; Beata Obrocka; Cezary Szczylik
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-27       Impact factor: 4.553

Review 10.  Systemic treatment options for untreated patients with metastatic clear cell renal cancer.

Authors:  Ana M Molina; Robert J Motzer; Daniel Y Heng
Journal:  Semin Oncol       Date:  2013-08       Impact factor: 4.929
  10 in total
  2 in total

1.  Unusual metastasis from renal cell cancer after partial nephrectomy and sequential targeted therapy.

Authors:  Shotaro Yasuoka; Takeshi Yuasa; Motohiro Fujiwara; Junko Fujisaki; Kentaro Inamura; Yoshinobu Komai; Noboru Numao; Shinya Yamamoto; Junji Yonese
Journal:  IJU Case Rep       Date:  2021-03-10

Review 2.  Progress of Phototherapy Applications in the Treatment of Bone Cancer.

Authors:  Jiachen Sun; Fei Xing; Joy Braun; Frank Traub; Pol Maria Rommens; Zhou Xiang; Ulrike Ritz
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.